Results 81 to 90 of about 6,841 (192)

TRMT6‐Mediated m1A Modification of CDK9 mRNA is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma

Advanced Science, Volume 13, Issue 39, 13 July 2026.
TRMT6‐mediated m1A modification in CDK9 mRNA enhances its mRNA stability and translation efficiency, thereby increasing the protein levels of CDK9. Upregulated CDK9 promotes the progression of HCC by elevating the levels of oncogenic factors including p‐STAT3, MCL1, and BCL‐2. On the other hand, CDK9 phosphorylates TARDBP at Ser254 to activate HBV core
Rui Zhang, Dandan Zong, Rui Liu, Yubo Wang, Qingqing Gu, Yao Yao, Wenfang Zheng, Mengmeng Yuan, Simeng Wang, Rongrong Cui, Daxu Li, Siwen Dang, Peng Hou   +12 more
wiley   +1 more source

Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment

Virology Journal, 2021
Background Serum hepatitis B virus RNA (HBV RNA) has been reported to be a surrogate marker of intrahepatic cccDNA during nucleos(t)ide analogs therapy.
Xiaomei Wang, Xiumei Chi, Ruihong Wu, Hongqin Xu, Xiuzhu Gao, Lei Yu, Longgen Liu, Mingxiang Zhang, Youwen Tan, Junqi Niu, Qinglong Jin   +10 more
doaj   +1 more source

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

MedComm, Volume 7, Issue 7, July 2026.
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang, Yiqiong Song, Ziyang Wang, Ke Chao, Lifeng Li, Xu Zhang, Xiaoran Duan, Chenglong Yu, Ruyue Xue, Jie Zhao   +9 more
wiley   +1 more source

RETRACTED: Parvulin 14 and Parvulin 17 Bind to HBx and cccDNA and Upregulate Hepatitis B Virus Replication from cccDNA to Virion in an HBx-Dependent Manner [PDF]

Journal of Virology, 2019
The HBx protein plays an essential regulatory role in HBV replication. We found that substrate-binding residues on the human parvulin peptidylprolyl cis / trans isomerase proteins Par14 and Par17 bound to conserved arginine-proline (RP) motifs on HBx in the cytoplasm, nucleus, and ...
Umar, Saeed, Jumi, Kim, Zahra Zahid, Piracha, Hyeonjoong, Kwon, Jaesung, Jung, Yong-Joon, Chwae, Sun, Park, Ho-Joon, Shin, Kyongmin, Kim   +8 more
openaire   +2 more sources

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

POLK is required for HBV cccDNA synthesis.

, 2016
(A) POLK expression in parental HepG2-NTCP cells and HepG2-NTCP cell clones bearing disrupted polk gene in one (HepG2-NTCPpolk+/-) or both alleles (HepG2-NTCPpolk-/-) was determined by Western blot assay. GAPDH protein served as a loading control.
Dingbin Tang (3254556), Ju-Tao Guo (304340), Guoliang Sun (3254559), Guangwei Xu (742674), Yang Liu (4829), Wenhui He (584851), Yinyan Sun (728290), Wenhui Li (396116), Zhenchao Gao (3254562), Yonghe Qi (457796), Chenxuan Liu (1602889), Zilin Song (426426), Bo Peng (273834), Qiyan Yao (3254565), Huan Yan (445452)   +14 more
core   +1 more source

Evolving Strategies in HBV Management: Insights From Updated International Guidelines

Hepatology Research, Volume 56, Issue 7, Page 1070-1078, July 2026.
Recent updates to WHO (2024), EASL (2025), and AASLD (2025) hepatitis B guidelines reflect divergent strategies, ranging from simplified public health‐oriented treatment expansion to biomarker‐driven precision medicine. Despite differences in treatment eligibility and nucleos(t)ide analogue discontinuation, all guidelines converge on early intervention
Masaru Enomoto, Grace Lai‐Hung Wong, Rui Huang, Mindie H. Nguyen   +3 more
wiley   +1 more source

Liver Transplantation for HBV‐Related Disease in France: NUC Type Before LT Is Associated With Patient Survival

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background & Aims Liver transplantation (LT) is indicated for liver complications related to hepatitis B virus (HBV) infection: acute liver failure (ALF), decompensated cirrhosis or hepatocellular carcinoma (HCC). The present study aimed to describe and evaluate patient survival after LT for HBV‐related disease in France and identify the ...
Isaure Bienvenue, Olivier Roux, Audrey Coilly, Armand Abergel, Teresa Antonini, Thierry Artzner, Olivier Boillot, Faiza Chermak, Filomena Conti, Sébastien Dharancy, Christophe Duvoux, Laure Elkrief, Marwin Farrugia, Claire Francoz, Baptiste Giguet, Jean Hardwigsen, Pauline Houssel‐Debry, Marie‐Noëlle Hilleret, Nassim Kamar, Marianne Latournerie, Magdalena Meszaros, Sylvie Radenne, Bruno Roche, Ephrem Salamé, Delphine Verhoeven‐Weil, Didier Samuel, Fabien Zoulim, Jérôme Dumortier, François Villeret   +28 more
wiley   +1 more source

Perspectives on NcRNAs in HBV/cccDNA-driven HCC progression

Cancer Cell International
Hepatitis B virus (HBV) integration, the HBx protein (and its mutants), and covalently closed circular DNA (cccDNA) are critical for HBV replication, packaging, and transmission to new host cells. Although nucleos(t)ide analogs (NAs) are a class of antiviral drugs that effectively suppress HBV replication, they do not eliminate cccDNA.
Yang-Hsiang Lin, Ming-Wei Lai, Chau-Ting Yeh, Wey-Ran Lin   +3 more
openaire   +3 more sources

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 170-188, June 2026.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source